Baird lowered the firm’s price target on Regenxbio to $37 from $42 and keeps an Outperform rating on the shares. The firm lowered their target on lower potential IP revenue but the EMBARK miss makes room for RGX-202 which they believe has a path to market, and now has a potentially better competitive opportunity to generate more robust data than Elevidys.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RGNX: